Toward in silico Identification of Tumor Neoantigens in Immunotherapy

Identification of tumor neoantigens has been facilitated by development of in silico methods or tools using high-throughput sequencing data. Neoantigens derived from single nucleotide variants (SNVs) and small insertions and deletions (INDELs) have been well-characterized in recent studies. Mutations derived from RNA editing, alternative splicing, and alleged noncoding regions have been demonstrated to generate neoantigens. Cancer immunotherapy...